Australia markets closed

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.35-0.10 (-1.06%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close9.45
Open9.41
Bid9.12 x 800
Ask12.30 x 1000
Day's range9.32 - 9.52
52-week range7.50 - 17.99
Volume15,759
Avg. volume23,701
Market cap326.121M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-4.16
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.00
  • Bloomberg

    DeepMind Co-Founder Suleyman Exits Google for VC Firm Greylock

    (Bloomberg) -- The co-founder of Google’s high-profile DeepMind artificial intelligence lab has left Alphabet Inc. to join venture capital firm Greylock Partners, following a turbulent tenure.Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapA Nor’easter Approaching New York Risks Becoming a Bomb CycloneMark Zuckerberg’s Stablecoin Ambitions Unravel With Diem Sale TalksNvidia Quietly Prepares to Abandon $40 Billion Arm BidTech Giants Rally Amid Bullish Outlo

  • GlobeNewswire

    Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

    OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The phase I/IIa trial is expected to enroll approximately 86 people who have been newly diagnosed with non-small cell lung cancer (NSCLC) and will be testing the safety and

  • GlobeNewswire

    Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

    Live webcast will be at 8:30 a.m. EST on January 25OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape. The